Loading...

Shandong Xinhua Pharmaceutical Company Limited

0719.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$7.88
HK$0.96(13.87%)

Shandong Xinhua Pharmaceutical Company Limited (0719.HK) Stock Overview

Explore Shandong Xinhua Pharmaceutical Company Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.9/100

Key Financials

Market Cap10.1B
P/E Ratio12.21
EPS (TTM)$0.68
ROE0.09%
Fundamental Analysis

AI Price Forecasts

1 Week$6.18
1 Month$5.95
3 Months$5.30
1 Year Target$6.45

0719.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Shandong Xinhua Pharmaceutical Company Limited (0719.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 78.85, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $6.45.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 12.21 and a market capitalization of 10.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

78.85RSI (14)
0.31MACD
46.31ADX
Revenue Growth
4.51%
↑ 4.51%
Profit Growth
HK$0.59
↓ 5.33%
EPS Growth
HK$0.59
↓ 6.76%
Operating Margin
6.02%
↓ 0.04%
ROE
8.91%
↓ 5.33%
Dividend Yield
0.00%
↑ 64.86%
Analyst Recommendations data is not available for 0719.HKAnalyst Recommendations details for 0719.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.

CEO

Tongqing He

Employees

7,296

Headquarters

Chemical Industry Area, Zibo

Founded

1996

Frequently Asked Questions

;